The stimulative function of long noncoding RNA CDKN2B-AS1 in osteosarcoma by targeting the microRNA-122/CCNG1 axis

Abula, Abulaiti; Saimaiti, Guliayixiamu; Maimaiti, Xayimardan; Wuqikun, Wumitijiang; Abulaiti, Alimujiang; Ren, Peng; Yusufu, Aihemaitijiang

doi:10.1080/10799893.2020.1850784

Cited by 6 publications

(4 citation statements)

References 33 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…For examples, in renal clear cell carcinoma, lncRNA CDKN2B-AS1 affected the malignancy through epigenetically activating NUF2 (NUF2 Component of NDC80 Kinetochore Complex) transcription [ 16 ]. Besides, CDKN2B-AS1 had a stimulative function in osteosarcoma and facilitates lung cancer development through their respective ways of regulation [ 43 ]. From the views of most reports, their conclusions about the role of lncRNAs CDKN2B-AS1 agreed with our findings and further verified that our results are reliable as well.…”

Section: Discussionmentioning

confidence: 99%

Knockdown of long non-coding RNA CDKN2B-AS1 suppresses the progression of breast cancer by miR-122-5p/STK39 axis

Qin

Ning

et al. 2021

Bioengineered

View full text Add to dashboard Cite

The lncRNAs have been made certain to take part in the development of most cancers in multiple ways. Here, our purpose is to making observation of the biological role and function of lncRNA CDKN2B-AS1 in human breast cancer. Twenty-eight pairs of breast cancer tissue and adjacent normal tissue from breast cancer patients were used to investigate the expression of CDKN2B-AS1 by qRT-PCR. And a lentivirus-shRNA guided CDKN2B-AS1 were to reduce its expression. The function of CDKN2B-AS1 was analyzed using a series of in vitro assays. Meanwhile, the xenograft model was used to further explicate the role of CDKN2B-AS1 in breast cancer. As for the results, there is a relative rich expression of CDKN2B-AS1 in breast cancer tissues compared with the corresponding adjacent normal tissues. Compared with the human breast epithelial cell line, the abundant expression of CDKN2B-AS1 in breast cancer cells were revealed as well. Then, knockdown CDKN2B-AS1 inhibited the malignant biological behaviors of MCF7 and T47D cells. In mechanism, CDKN2B-AS1 sponged the miR-122-5p to regulate STK39 expression. Furthermore, the inhibition effect with sh-CDKN2B-AS1 on breast cancer cells was alleviated by miR-122-5p inhibitor. Last, an in vivo model also confirmed that knockdown CDKN2B-AS1 retarded the growth of breast cancer. Our data concluded that knockdown of CDKN2B-AS1 suppresses the progression of breast cancer by miR-122-5p/STK39 axis.

show abstract

Section: Discussionmentioning

confidence: 99%

Knockdown of long non-coding RNA CDKN2B-AS1 suppresses the progression of breast cancer by miR-122-5p/STK39 axis

Qin

Ning

et al. 2021

Bioengineered

View full text Add to dashboard Cite

show abstract

“…The CCNG1 gene itself is subject to dysregulation by the action of oncogenic long-noncoding RNAs ( Cheng et al, 2018 ; Li et al, 2019 ; Abula et al, 2022 ); and by direct/activating mutations. A close examination of the pathogenesis of Burkitt’s lymphoma in a screening for IG-translocations to non-MYC partners that could cooperate with MYC in pathogenesis, identified a telltale IGK-GGNG1 translocation: a chromosomal breakpoint at the CCNG1 promoter that had apparently occurred earlier (at pre-B or immature B Cell stage) in the evolution of the tumor, which suggested that IG-MYC translocations may not always be the initial genetic event in Burkitt’s lymphoma ( López et al, 2019 ).…”

Section: A Proximal Oncology: Pioneering a Proximal And Accessible Lo...mentioning

confidence: 99%

The advent of a pan-collagenous CLOVIS POINT for pathotropic targeting and cancer gene therapy, a retrospective

Gordon

Hall²

2023

Front. Mol. Med

View full text Add to dashboard Cite

The ‘Clovis Point’—an enabling prehistoric gain-of-function in stone-age tool technologies which empowered the Paleoindian-Americans to hunt, to strike-deep, and to kill designated target megafauna more efficiently—was created biochemically by molecular-genetic bio-engineering. This Biomedical “Clovis Point” was crafted by adapting a broad-spectrum Pan-Collagen Binding Domain (Pan-Coll/CBD) found within the immature pre-pro-peptide segment of Von Willebrand Factor into a constructive series of advanced medical applications. Developed experimentally, preclinically, and clinically into a cutting-edge Biotechnology Platform, the Clovis Point is suitable for 1) solid-state binding of growth factors on collagenous scaffolds for improved orthopedic wound healing, 2) promoting regeneration of injured/diseased tissues; and 3) autologous stem cell capture, expansion, and gene-based therapies. Subsequent adaptations of the high-affinity Pan-Coll/CBD (exposed-collagen-seeking/surveillance function) for intravenous administration in humans, enabled the physiological delivery, aka Pathotropic Targeting to diseased tissues via the modified envelopes of gene vectors; enabling 4) precision tumor-targeting for cancer gene therapy and 5) adoptive/localized immunotherapies, demonstrating improved long-term survival value—thus pioneering a proximal and accessible cell cycle control point for cancer management—empowering modern medical oncologists to address persistent problems of chemotherapy resistance, recurrence, and occult progression of metastatic disease. Recent engineering adaptations have advanced the clinical utility to include the targeted delivery of small molecule APIs: including taxanes, mAbs, and RNA-based therapeutics.

show abstract

“…CDKN2B-AS1 induces renal clear cell carcinoma by recruiting CREB-binding proteins and three epigenetically modified complexes comprising SET and MYND structural domains to the NUF2 promoter region [6]. In addition, CDKN2B-AS1 works as a sponge in lung cancer, adsorbing miR-378b and regulating miR-378b/NR2C2 [7]. However, so far, few studies have investigated how CDKN2B-AS1 plays a role in TC.…”

Section: Introductionmentioning

confidence: 99%

lncRNA CDKN2B-AS1 Could Be an Indicator to Identify Prognosis and Status of Immune Microenvironment in Thyroid Cancer

et al. 2022

View full text Add to dashboard Cite

Thyroid cancer (TC) is prone to recurrence, and biomarkers for predicting progression-free interval (PFI) are poorly explored. The study investigates the predictive value and underlying biological mechanisms of lncRNA CDKN2B-AS1 in TC. Combining RNA-seq and survival data, we identified that CDKN2B-AS1 was upregulated in TC samples and could be an excellent prognostic indicator. To exclude confounding factors, we divided patients into different subgroups using median CDKN2B-AS1 expression, and the effects of CDKN2B-AS1 on PFI and clinical features were explored in different clinical subgroups. Meanwhile, ssGSEA and ESTIMATE algorithms revealed that CDKN2B-AS1 overexpression may suggest the active state of the immune microenvironment. On the other hand, enrichment analysis also proved the potential influence of CDKN2B-AS1 on immune regulation in TC. Finally, we created a CDKN2B-AS1, microRNAs, and TFs network and discovered a new biomarker (CDKN2B-AS1) that might be employed as a therapeutic target in TC patients.

show abstract

The stimulative function of long noncoding RNA CDKN2B-AS1 in osteosarcoma by targeting the microRNA-122/CCNG1 axis

Cited by 6 publications

References 33 publications

Knockdown of long non-coding RNA CDKN2B-AS1 suppresses the progression of breast cancer by miR-122-5p/STK39 axis

Knockdown of long non-coding RNA CDKN2B-AS1 suppresses the progression of breast cancer by miR-122-5p/STK39 axis

The advent of a pan-collagenous CLOVIS POINT for pathotropic targeting and cancer gene therapy, a retrospective

lncRNA CDKN2B-AS1 Could Be an Indicator to Identify Prognosis and Status of Immune Microenvironment in Thyroid Cancer

Contact Info

Product

Resources

About